Carrier-free reduction-responsive self-assembling paclitaxel dimer nanoprodrug synergizing with celastrol for enhanced chemoimmunotherapy

Yudi Lu , Mei Zhou , Xunfa Zhang , Weijun Huang , Fan Li , Ning Li Zhang , Nannan Lu , Chenggui Wu , Zhihui Feng , Shuangying Gui , Zhenbao Li

Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) : 101124

PDF (5903KB)
Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) :101124 DOI: 10.1016/j.ajps.2026.101124
Research Article
research-article
Carrier-free reduction-responsive self-assembling paclitaxel dimer nanoprodrug synergizing with celastrol for enhanced chemoimmunotherapy
Author information +
History +
PDF (5903KB)

Abstract

Chemotherapeutic paclitaxel (PTX) formulations are widely used in clinical cancer treatment; however, they are also associated with concomitant programmed death-ligand (PD-L1) upregulation and an immunosuppressive microenvironment. Herein, we rationally designed carrier-free, reduction-sensitive PTX dimer self-assembling nanoprodrugs (diPC NPs), composed of a glutathione (GSH)-responsive PTX dimer prodrug (diPTX) and the PD-L1 downregulator celastrol (Cel) for combinational chemoimmunotherapy. Following intravenous administration, the diPC NPs exhibited prolonged blood circulation and preferential tumor accumulation by exploiting the enhanced permeability and retention effect. Subsequently, the elevated GSH levels in tumor cells cleaved the disulfide bonds, triggering the rapid release of PTX and Cel. The released PTX elicited potent cytotoxic effects and induced immunogenic cell death (ICD), whereas the released Cel synergistically enhanced ICD and downregulated PD-L1 expression in tumor cells. Together, these effects resulted in remarkable antitumor efficacy with exhibited a favorable safety profile within the therapeutic window in both Lewis lung carcinoma cells and B16F10 tumor-bearing mice. Our findings highlight a promising strategy for highly efficient combination chemoimmunotherapy.

Keywords

Carrier-free / Reduction-responsive / self-assembling / Paclitaxel dimer / Nanoprodrug / Celastrol / Chemoimmunotherapy

Cite this article

Download citation ▾
Yudi Lu, Mei Zhou, Xunfa Zhang, Weijun Huang, Fan Li, Ning Li Zhang, Nannan Lu, Chenggui Wu, Zhihui Feng, Shuangying Gui, Zhenbao Li. Carrier-free reduction-responsive self-assembling paclitaxel dimer nanoprodrug synergizing with celastrol for enhanced chemoimmunotherapy. Asian Journal of Pharmaceutical Sciences, 2026, 21 (1) : 101124 DOI:10.1016/j.ajps.2026.101124

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74(3): 229-63.

[2]

Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer 2022; 22(6): 323-39.

[3]

Letai A, de The H. Conventional chemotherapy: millions of cures, unresolved therapeutic index. Nat Rev Cancer 2025; 25(3): 209-18.

[4]

Sun L, Zuo C, Ma B, Liu X, Guo Y, Wang X, et al. Intratumoral injection of two dosage forms of paclitaxel nanoparticles combined with photothermal therapy for breast cancer. Chin Herb Med 2025; 17(1): 156-65.

[5]

Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000; 88(11): 2619-28.

[6]

Xie S, Ogden A, Aneja R, Zhou J. Microtubule-binding proteins as promising biomarkers of paclitaxel sensitivity in cancer chemotherapy. Med Res Rev 2016; 36(3): 300-12.

[7]

Zhang B, Zhou S, Lu S, Xiang X, Yao X, Lei W, et al. Paclitaxel prodrug enables glutathione depletion to boost cancer treatment. ACS Nano 2024; 18(40): 26690-703.

[8]

Galluzzi L, Guilbaud E, Schmidt D, Kroemer G, Marincola FM. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov 2024; 23(6): 445-60.

[9]

Serpico AF, Pisauro C, Grieco D. cGAS-dependent proinflammatory and immune homeostatic effects of the microtubule-targeting agent paclitaxel. Front Immunol 2023; 14: 1127623.

[10]

Hu N, Xue H, Zhang T, Fan Y, Guo F, Li Z, et al. Harnessing PD-1 cell membrane-coated paclitaxel dimer nanoparticles for potentiated chemoimmunotherapy. Biomed Pharmacother 2024; 174: 116482.

[11]

Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer 2022; 21(1): 28.

[12]

Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martín-Liberal J, Joerger M, et al. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature 2025; 637(8031): 1218-27.

[13]

Nielsen DL, Juhl CB, Nielsen OH, Chen IM, Herrmann J. Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Oncol 2024; 10(10): 1390-9.

[14]

Yue Y, Su L, Wang Y, Li X, Xiao X, Xie J, et al. Banxia Xiexin decoction inhibits colitis-associated colorectal cancer development by modulating STAT3 signaling and gut microbiota. Chin Herb Med 2025; 17(3): 380-91.

[15]

Qian X, Liu Y, Chen W, Zheng S, Lu Y, Qiu P, et al. Paris saponin VII induces caspase-3/GSDME-dependent pyroptosis in pancreatic ductal adenocarcinoma cells by activating ROS/bax signaling. Chin Herb Med 2025; 17(1): 94-107.

[16]

Wang CY, Bai XY, Wang CH. Traditional Chinese medicine: a treasured natural resource of anticancer drug research and development. Am J Chin Med 2014; 42(3): 543-59.

[17]

Wang C, Dai S, Zhao X, Zhang Y, Gong L, Fu K, et al. Celastrol as an emerging anticancer agent: current status, challenges and therapeutic strategies. Biomed Pharmacother 2023; 163: 114882.

[18]

Qiu N, Liu Y, Liu Q, Chen Y, Shen L, Hu M, et al. Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy. Biomaterials 2021; 269: 120604.

[19]

Li HF, Zhu N, Wu JJ, Shi YN, Gu J, Qin L. Celastrol elicits antitumor effects through inducing immunogenic cell death and downregulating PD-L1 in ccRCC. Curr Pharm Des 2024; 30(15): 1265-78.

[20]

Ji Y, Hao J, Tao X, Li Z, Chen L, Qu N. Preparation and anti-tumor activity of paclitaxel silk protein nanoparticles encapsulated by biofilm. Pharm Dev Technol 2024; 29(5): 627-38.

[21]

Zhang X, Chen Y, Li X, Xu H, Yang J, Wang C, et al. Carrier-free self-assembled nanomedicine based on celastrol and galactose for targeting therapy of hepatocellular carcinoma via inducing ferroptosis. Eur J Med Chem 2024; 267: 116183.

[22]

Subbaiah MAM, Rautio J, Meanwell NA. Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates. Chem Soc Rev 2024; 53(6): 2099-210.

[23]

Ciftci F, Özarslan AC, İmran CK, Yelkenci A, Tavukcuoglu O, Ghorbanpour M. Advances in drug targeting, drug delivery, and nanotechnology applications: therapeutic significance in cancer treatment. Pharmaceutics 2025; 17(1): 121.

[24]

Li G, Sun B, Li Y, Luo C, He Z, Sun J. Small-molecule prodrug nanoassemblies: an emerging nanoplatform for anticancer drug delivery. Small 2021; 17(18): e2101460.

[25]

Li Y, Sun Y, Yan Q, Wang W, Wang S, Wang Q, et al. Redox-triggered prodrug nanoassemblies with high tumor selectivity and biocompatibility break through antitumor dilemma of paclitaxel. Chinese Chem Lett 2025: 111350.

[26]

Zhang Y, Zhang W, Wang Y, Zhu J, Zhou M, Peng C, et al. Emerging nanotaxanes for cancer therapy. Biomaterials 2021; 272: 120790.

[27]

Luo C, Sun B, Wang C, Zhang X, Chen Y, Chen Q, et al. Self-facilitated ROS-responsive nanoassembly of heterotypic dimer for synergistic chemo-photodynamic therapy. J Control Release 2019; 302: 79-89.

[28]

Li F, Wang W, Xu W, Li W, Lu Y, Wang R, et al. Traditional Chinese medicine-facilitated redox-labile paclitaxel dimer nanoprodrug for efficient chemoimmunotherapy. J Pharm Anal 2025: 101348.

[29]

Sun B, Luo C, Zhang X, Guo M, Sun M, Yu H, et al. Probing the impact of sulfur/selenium/carbon linkages on prodrug nanoassemblies for cancer therapy. Nat Commun 2019; 10(1): 3211.

[30]

Liu T, Li L, Wang S, Dong F, Zuo S, Song J, et al. Hybrid chalcogen bonds in prodrug nanoassemblies provides dual redox-responsivity in the tumor microenvironment. Nat Commun 2022; 13(1): 7228.

[31]

Zhang H, Liu T, Sun Y, Wang S, Wang W, Kuang Z, et al. Carbon-spaced tandem-disulfide bond bridge design addresses limitations of homodimer prodrug nanoassemblies: enhancing both stability and activatability. J Am Chem Soc 2024; 146(32): 22675-88.

[32]

Pei Q, Hu X, Liu S, Li Y, Xie Z, Jing X. Paclitaxel dimers assembling nanomedicines for treatment of cervix carcinoma. J Control Release 2017; 254: 23-33.

[33]

Qian X, Yang H, Ye Z, Gao B, Qian Z, Ding Y, et al. Celecoxib augments paclitaxel-induced immunogenic cell death in triple-negative breast cancer. ACS Nano 2024; 18(22): 15864-77.

[34]

Yang Y, Liu X, Zhang R, Liu Y, Zhou N, Jiang Y. Size-tunable micro-nano liposomes: enhanced lung targeting and tumor penetration for combination treatment of lung cancer. Small 2025; 21(2): e2409593.

[35]

Li L, Wang H, Zhang S, Gao S, Lu X, Pan Y, et al. Statins inhibit paclitaxel-induced PD-L1 expression and increase CD8+ T cytotoxicity for better prognosis in breast cancer . Int J Surg 2024; 110: 4716-26.

[36]

Geng Y, Xiang J, Shao S, Tang J, Shen Y. Mitochondria-targeted polymer-celastrol conjugate with enhanced anticancer efficacy. J Control Release 2022; 342: 122-33.

PDF (5903KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉